Written questions by Evans.

What assessment he has made of the adequacy of (a) fresh-freezing, (b) snap-freezing and (c) flash frozen capacity for brain cancer tissue samples across NHS trusts in England.

Fresh-freezing, also referred to as snap-freezing, is a standard technique used by pathology networks to preserve tissue architecture without chemical fixatives, allowing for subsequent molecular or histological analysis, typically supporting research or advanced diagnostic applications.Pathology services in England are delivered through 27 regional pathology networks, and offer a comprehensive range of tests, including the analysis of brain tissues.Individual pathology services maintain their own standard operating procedures (SOPs) for fresh tissue samples and for the snap-freezing of tissue samples. These SOPs outline local capabilities and practices.It is important that everyone, regardless of where they live, can access the latest innovations in the health and care system through research. The Department invests over £1.6 billion each year in research through the National Institute of Health and Care Research (NIHR). The NIHR’s investments for capital equipment, technology, and modular buildings support NHS trusts across England to deliver high-quality research to improve the health of the population. This investment includes cutting edge research equipment and fixed assets such as ultra-low and cryogenic freezers, to strengthen research capacity and improve access to samples for research.The Department is exploring options to expand brain tissue freezing capacity.

If he will make an assessment of the adequacy of the NHS’s capacity for fresh freezing of (a) tumour and (b) other tissue samples.

Fresh-freezing, also referred to as snap-freezing, is a standard technique used by pathology networks to preserve tissue architecture without chemical fixatives, allowing for subsequent molecular or histological analysis, typically supporting research or advanced diagnostic applications.Pathology services in England are delivered through 27 regional pathology networks, and offer a comprehensive range of tests, including the analysis of brain tissues.Individual pathology services maintain their own standard operating procedures (SOPs) for fresh tissue samples and for the snap-freezing of tissue samples. These SOPs outline local capabilities and practices.It is important that everyone, regardless of where they live, can access the latest innovations in the health and care system through research. The Department invests over £1.6 billion each year in research through the National Institute of Health and Care Research (NIHR). The NIHR’s investments for capital equipment, technology, and modular buildings support NHS trusts across England to deliver high-quality research to improve the health of the population. This investment includes cutting edge research equipment and fixed assets such as ultra-low and cryogenic freezers, to strengthen research capacity and improve access to samples for research.The Department is exploring options to expand brain tissue freezing capacity.

What recent progress has been made by the (a) Medicines and Healthcare Products Regulatory Agency and (b) the Commission on Human Medicines to (i) understand the (A) current and (B) historic risks of sodium valproate when taken during pregnancy, and (ii) in communicating these risks to (1) healthcare professionals and (2) patients.

The Medicines and Healthcare products Regulatory Agency (MHRA), taking advice from the Commission on Human Medicines (CHM), has worked to raise awareness among healthcare professionals and patients of the risks of valproate when taken during pregnancy through several updates to the valproate Summary of Product Characteristics, for healthcare professionals, and the Patient Information Leaflets, as well as updates to associated educational materials as required.The magnitude and type of risks associated with valproate use in pregnancy have been communicated in articles in the MHRA bulletin, Drug Safety Update, and via letters cascaded out through the NHS Central Alerting System. These communications have been supported by messages from the relevant professional bodies and regulatory requirements reinforced through changes to clinical guidelines and improved alerts on general practitioner prescribing systems.The valproate Pregnancy Prevention Programme, implemented in 2018, is supported by educational materials for healthcare professionals and patients which describe the neurodevelopmental disorders and major congenital malformations associated with the use of valproate in pregnancy, and are available electronically and sent in hard copy format to healthcare professionals.In January 2024, the MHRA communicated, in an article in a Drug Safety Update, the latest advice from the CHM, that valproate must not be started in new patients, male or female, younger than 55 years old unless two specialists independently consider and document that there is no other effective or tolerated treatment, or if there are compelling reasons that the reproductive risks do not apply. It was advised that women and girls of childbearing potential who are already receiving valproate should have their treatment reviewed by two specialists at their next annual review. The requirement for two specialists to review these patients is a one off, and subsequent annual reviews required under the Pregnancy Prevention Programme are undertaken by a single specialist.Updated educational materials were made available to healthcare professionals and patients electronically, and sent to healthcare professionals in hard copy format, that could be provided to patients and which could support the discussions between healthcare professionals and patients.